Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 15.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 2,387,352 shares of the company's stock after purchasing an additional 326,095 shares during the period. JPMorgan Chase & Co. owned about 5.53% of Kyverna Therapeutics worth $11,674,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC acquired a new stake in Kyverna Therapeutics in the 3rd quarter valued at approximately $33,000. Creative Planning purchased a new position in Kyverna Therapeutics in the 3rd quarter valued at approximately $54,000. Jacobs Levy Equity Management Inc. purchased a new position in Kyverna Therapeutics in the 3rd quarter valued at approximately $97,000. Federated Hermes Inc. purchased a new position in Kyverna Therapeutics in the 2nd quarter valued at approximately $120,000. Finally, BNP Paribas Financial Markets boosted its position in Kyverna Therapeutics by 2,166.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 27,197 shares of the company's stock valued at $133,000 after buying an additional 25,997 shares during the period. Institutional investors and hedge funds own 18.08% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Wells Fargo & Company decreased their price target on shares of Kyverna Therapeutics from $44.00 to $24.00 and set an "overweight" rating for the company in a research report on Friday, November 15th. Rodman & Renshaw assumed coverage on shares of Kyverna Therapeutics in a research report on Wednesday, October 9th. They issued a "buy" rating and a $16.00 price target for the company. RODMAN&RENSHAW raised shares of Kyverna Therapeutics to a "strong-buy" rating in a research report on Wednesday, October 9th. HC Wainwright decreased their price objective on shares of Kyverna Therapeutics from $7.00 to $6.00 and set a "neutral" rating for the company in a research report on Wednesday, November 20th. Finally, UBS Group started coverage on shares of Kyverna Therapeutics in a research report on Thursday, October 10th. They set a "buy" rating and a $13.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Kyverna Therapeutics presently has a consensus rating of "Buy" and an average price target of $25.71.

Kyverna Therapeutics Price Performance

KYTX traded down $0.16 on Monday, reaching $3.29. The company had a trading volume of 357,776 shares, compared to its average volume of 294,760. Kyverna Therapeutics, Inc. has a 1 year low of $3.28 and a 1 year high of $35.06. The stock has a 50-day moving average price of $4.51 and a 200-day moving average price of $6.13.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.01. The company had revenue of $0.01 million during the quarter. As a group, sell-side analysts anticipate that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.